Cite
HARVARD Citation
Cohen, S. et al. (2021). Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift). RMD open. 7 (2), p. . [Online].